Patients Taking Losmapimod Experience No Improvement After Heart Attack


The anti-inflammatory drug failed to meet primary endpoints in patients who suffered an acute heart attack.

Inflammation after a heart attack is a large risk that can increase additional cardiovascular risks. Due to inflammation, patients can experience less healing of the tissue, increased plaque formation, and possibly another heart attack.

In a study presented at the American College of Cardiology's 65th Annual Scientific Session, researchers found no improvement among patients taking the anti-inflammatory drug losmapimod for 12 weeks after a heart attack.

Losmapimod inhibits the p38 mitogen-activated protein kinase, which is an enzyme in heart muscle. It is activated by different heart related stressors, including heart attacks.

In this study, 3500 patients who suffered acute heart attacks were given this drug and their progress was monitored. Half of the patients received 7.5 milligrams of losmapimod twice per day and half received a placebo.

The researchers hoped the see a decrease in deaths, cardiovascular revascularization, and another heart attack.

After 12 weeks of monitoring the patients, researchers found that there was no difference between those who received the placebo and those taking losmapimod.

Due to this finding, the trial failed to reach its endpoint and did not continue any further.

Researchers remain hopeful losmapimod may be able to help different subgroups, such as patients who have experienced a more severe heart attack.

Losmapimod was observed to have what the researchers call “interesting signals” in regards to patients who had a more severe heart attack, such as ST-segment elevation myocardial infarction. They believe that conducting more trials within that subgroup may prove the efficacy of the drug.

"We are intrigued by the potential signal towards benefit, which was supported, at least in concept, by an earlier study that showed favorable effects in terms of left ventricular function following myocardial infarction,” Michelle O'Donoghue, MD said in a press release. “Thus, it remains possible that losmapimod may have favorable effects on healing of the heart after a heart attack, but that would require a separate study.

A future study that addresses the limitations of the current study, such as duration and focusing on specific groups could prove the efficacy of losmapimod.

Related Videos
Woman with pink ribbon on color background. Breast cancer awareness concept | Image Credit: Pixel-Shot -
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store- Image credit: C Daniels/ |
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto -
A female doctor sits at her desk and talks to a female patient while looking at her mammogram | Image Credit: lordn -
Doctor holding a digital tablet with x-ray of brain and skull skeleton. Headache, meningitis and migraine concept - Image credit: Steph photographies |
Woman Physician Talking With Her Patient | Image Credit: LStockStudio -
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint |
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan |
© 2023 MJH Life Sciences

All rights reserved.